Cardiovascular effects of cholecalciferol treatment in dialysis patients – a randomized controlled trial

BMC Nephrology

Table 2 Effect of cholecalciferol (Vitamin D3) treatment on calcium metabolism and vasoactive hormones in a randomized, placebo-controlled study of 50 patients on dialysis

	Baseline	6 months	P value (difference in response)
P-25(OH)D (nmol/L)
Placebo	28 (20;69)	30 (22;50)	<0.001
Cholecalciferol	28 (20;48)	84 (65;125)*	<0.001
P-PTH (pmol/L)
Placebo	18.0 (5.9;30.5)	12.9 (8.7;33.7)	0.986
Cholecalciferol	13.5 (5.8;29.6)	17.4 (9.1;35.3)	0.986
P-Ca ²⁺ (mg/dL)
Placebo	1.20 ± 0.08	1.20 ± 0.07	0.724
Cholecalciferol	1.21 ± 0.11	1.20 ± 0.09	0.724
P-Phosphate (nmol/L)
Placebo	1.66 ± 0.37	1.59 ± 0.38	0.103
Cholecalciferol	1.59 ± 0.40	1.73 ± 0.47	0.103
P-Alkaline Phosphatase (U/L)
Placebo	67 (51;99)	72 (59;93)	0.393
Cholecalciferol	70 (48;92)	73 (48;106)	0.393
P-CRP (mg/L)
Placebo	4.5 (1.7;11.7)	2.5 (1.6;13.9)	0.237
Cholecalciferol	3.4 (1.1;13.3)	3.9 (1.1;11.3)	0.237
P-leukocytes (10 ⁹ /L)
Placebo	6.3 (5.2;7.7)	6.3 (5.6;7.3)	0.740
Cholecalciferol	6.3 (5.1;7.5)	5.8 (5.2;8.1)	0.740
P-Haemoglobin (mmol/L)
Placebo	7.3 ± 0.8	7,3 ± 0.7	0. 419
Cholecalciferol	7.4 ± 0.8	7.2 ± 0.6	0. 419
P-BNP (pmol/L)
Placebo	81 (24;186)	50 (30;265)	0.820
Cholecalciferol	61 (26;378)	95 (35;363)	0.820
PRC (pg/mL)
Placebo	10 (4;19)	8 (6;23)	0.883
Cholecalciferol	6 (4;12)	8 (4;20)	0.883
P-Ang II (pg/mL)
Placebo	12 (7;23)	15 (4;33)	0.167
Cholecalciferol	7 (3;26)	12 (5;60)	0.167
P-Aldosterone (pmol/L)
Placebo	135 (49;300)	209 (68;329)	0.415
Cholecalciferol	125 (61;250)	155 (76;312)	0.415

Values are mean ± SD or medians with 25 and 75 percentiles in brackets. 25(OH): 25-hydroxy-vitamin D, PTH: parathyroid hormone, CRP, C-reactive protein, BNP: Brain natriuretic peptide, PRC: Plasma renin concentration, Ang II: Angiotensin II, P values represent the probability of a difference in response to treatment between groups. Statistical significant difference from baseline: * = p < 0.001.

ISSN: 1471-2369